Pulse Biosciences reported a Q2 2025 net loss of $0.28 per share, slightly wider than estimates, with no revenue. The company advances its nsPFA tech in clinical trials, focusing on atrial fibrillation and thyroid treatments. Cash reserves stand at $106.3M.
The regular session of the US market on Wednesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
The Russell 2000 index of small caps recorded its best weekly performance since October 2023, surging over 6%, driven by lower-than-expected June inflation data and potential interest rate cuts.
Shares of Nuvve Holding Corp. (NASDAQ: NVVE) fell sharply during Monday’s session after the company reported worse-than-expected fourth-quarter financial results.
